Issue link: https://viewer.e-digitaledition.com/i/1049957
" The NewYork-Presbyterian Lawrence Hospital Cancer Center offers a personalized, patient-centered approach with the vast expertise and resources of the NCI-designated Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center." — HENRY J. LEE, MD, PHD, DIRECTOR OF RADIATION ONCOLOGY AT NYP LAWRENCE AND ASSISTANT PROFESSOR OF RADIATION ONCOLOGY AT COLUMBIA UNIVERSITY MEDICAL CENTER Dr. Wasserheit is a medical oncologist with more than two decades of experience. She is a dedicated and compassionate clinician who treats her patients with a highly personalized approach to care. The NewYork-Presbyterian Lawrence Hospital Cancer Center team regularly meets to discuss complex and unusual patient cases. Meetings can include oncologists, surgeons, pathologists, nurses, social workers, dietitians and other staff. patient's individual needs and clinical and family histories, rather than automatically performing broad-spectrum testing on every patient, which can create anxiety without being informative. Tabanfar consults with patients further if results are positive, and the medical recommendations can be much more aggressive. For breast cancer patients with a BRCA1 mutation, for example, the breast cancer disease management team might recommend risk-reduction surgery, such as double mastectomy or removal of the ovaries. Those are not easy decisions, but having access to reliable information about germline mutations — those that parents pass on to their offspring — empowers patients in charting an informed course of treatment, Tabanfar says. PROFILING TUMORS Presently, while heredita r y genetics t es t i n g play s a n i mpor t a nt role i n management of some cancers, learning more about tumors can provide insight i nto v i r t ua l ly ever y t y pe of ca ncer, according to Dr. Lee. NYP Lawrence's pat holog ist s use a ra nge of test s to ana lyze tumors in collaboration with Columbia pathologists. In addition to testing to determine a recurrence score for applicable early-stage breast cancer patients, other genomic and biomarker analyses are used in metastatic breast cancer tumors and non-small cell lung, colorectal and ovarian cancers, as well as melanomas. " T he s e a n d ot her t e s t s ident i f y a pat ient 's u n ique a lt er at ion s i n a t u mor 's prot e om ic s , genom ic s a nd epigenetics," Dr. Lee says. Analyzing those molecular biomarkers helps physicians customize treatment. "Precision medicine has the potential to improve the therapeutic index of radiation therapy in particular by a llowing the radiation oncologist to individua lize a patient 's treatments to a degree far greater than we've been able to do over the past 100 years," Dr. Lee says. "The radiation oncologist can maximize tumor control while minimizing the toxicity of radiation therapy." TREATING TUMORS Once testing provides a detailed analysis of a tumor, Dr. Lee may employ intensity- modulated radiation therapy (IMRT) or stereotactic body radiosurgery therapy (SBRT) as part of the precision medicine- guided course of treatment. Both forms of radiation therapy target tumors with superb accuracy. SBRT delivers a much lower dose of radiation to normal tissues surrounding a tumor a nd provides a much higher dose of radiation to the tumor, which means fewer clinic visits for patients. In addition to radiation therapy, the information gleaned through genetic testing informs other potential courses of treatment as well, whether chemotherapy, immunotherapy, surgery or different combinations of all of these approaches. M D N E W S . C O M /// M D N E W S L O W E R H u D S O N / B R O N x ■ 2 018 0 9

